Annexon Inc. (ANNX)
NASDAQ: ANNXHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ANNX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $760.21M
- EPS (TTM)
- -$1.13
- Dividend yield
- None
- 52-week range
- 2.54 – 7.18
- Day range
- 3.91 – 4.18
- Volume / Avg
- 2.45M / 3.19M
- Beta
- —
- Shares outstanding
- 189.58M
52-week range
ANNX stock today
Annexon (ANNX) closed at $4.01 on Oct 7, down 0.50% (-$0.02), versus the S&P 500's 0.22% decline. Shares are 44.2% below their 52-week high of $7.18, set on Jan 23, 2026 and 57.9% above the 52-week low of $2.54, in the middle of the past year's range. ANNX is down 20.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 30.6%.
Annexon has posted a net loss over the last twelve months (EPS of -$1.13), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Annexon
Company profileAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Douglas E. Love Esq., J.D.
- Headquarters
- Brisbane, CA
- Employees
- 92
- IPO year
- 2020
- Website
- annexonbio.com
Analyst forecast
ForecastConsensus (10 analysts)
buy
Avg. price target
$15.43+284.79%
- Strong buy 2
- Buy 6
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Annexon peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HELPHelus Pharma Inc. | 10.51 | -2.32% | $767.86M | vs ANNX |
| GERNGeron Corporation | 1.20 | -0.83% | $770.97M | vs ANNX |
| DNAGinkgo Bioworks Holdings Inc. Class A | 11.47 | -7.57% | $772.39M | vs ANNX |
| CADLCandel Therapeutics Inc. | 9.82 | -0.51% | $751.41M | vs ANNX |
| APMDApnimed Inc. | 18.04 | -3.27% | $751.02M | vs ANNX |
| ATTOAttovia Therapeutics Inc. | 16.42 | -6.17% | $749.59M | vs ANNX |
| VSTMVerastem Inc. | 8.27 | +6.65% | $748.51M | vs ANNX |
| GYREGyre Therapeutics Inc. | 7.04 | -0.56% | $746.48M | vs ANNX |
Indexes, lists and sector
Appears in lists
Annexon stock FAQ
What is Annexon's stock price today?
ANNX last traded at $4.01 as of Oct 7, 4:00 PM EDT, down 0.50% on the day. Prices are delayed at least 15 minutes.
Who is Annexon's CEO?
Mr. Douglas E. Love Esq., J.D. is the chief executive officer of Annexon Inc., which has about 92 employees.
What is the ANNX 52-week high?
The 52-week high for ANNX is $7.18 and the 52-week low is $2.54. The stock is currently 44.2% below its high.